The predefined secondary efficacy outcomes
included each component of the primary efficacy
outcome, as well as death from cardiovascular
causes and death from any cause. An additional
predefined secondary outcome was the composite
of symptomatic recurrent venous thromboembolism
with death from cardiovascular causes,
with death from any cause, or with death related
to venous thromboembolism plus major bleeding.